OBJECTIVE: Neonatal invasive candidiasis is associated with significant morbidity and mortality. We describe the association between invasive candidiasis and changes in use of antifungal prophylaxis, empirical antifungal therapy, and broad-spectrum antibacterial antibiotics over time. METHODS: We examined data from 709,325 infants at 322 NICUs managed by the Pediatrix Medical Group from 1997 to 2010. We determined the cumulative incidence of invasive candidiasis and use of antifungal prophylaxis, broad-spectrum antibacterial antibiotics, and empirical antifungal therapy by year. RESULTS: We identified 2063 (0.3%) infants with 2101 episodes of invasive candidiasis. Over the study period, the annual incidence of invasive candidiasis decreased from 3.6 episodes per 1000 patients to 1.4 episodes per 1000 patients among all infants, from 24.2 to 11.6 episodes per 1000 patients among infants with a birth weight of 750-999 g, and from 82.7 to 23.8 episodes per 1000 patients among infants with a birth weight <750 g. Fluconazole prophylaxis use increased among all infants with a birth weight <1000 g (or <1500 g), with the largest effect on birth weights <750 g, increasing from 3.8 per 1000 patients in 1997 to 110.6 per 1000 patients in 2010. The use of broad-spectrum antibacterial antibiotics decreased among all infants from 275.7 per 1000 patients in 1997 to 48.5 per 1000 patients in 2010. The use of empirical antifungal therapy increased over time from 4.0 per 1000 patients in 1997 to 11.5 per 1000 patients in 2010. CONCLUSIONS: The incidence of invasive candidiasis in the NICU decreased over the 14-year study period. Increased use of fluconazole prophylaxis and empirical antifungal therapy, along with decreased use of broad-spectrum antibacterial antibiotics, may have contributed to this observation.
OBJECTIVE: Neonatal invasive candidiasis is associated with significant morbidity and mortality. We describe the association between invasive candidiasis and changes in use of antifungal prophylaxis, empirical antifungal therapy, and broad-spectrum antibacterial antibiotics over time. METHODS: We examined data from 709,325 infants at 322 NICUs managed by the Pediatrix Medical Group from 1997 to 2010. We determined the cumulative incidence of invasive candidiasis and use of antifungal prophylaxis, broad-spectrum antibacterial antibiotics, and empirical antifungal therapy by year. RESULTS: We identified 2063 (0.3%) infants with 2101 episodes of invasive candidiasis. Over the study period, the annual incidence of invasive candidiasis decreased from 3.6 episodes per 1000 patients to 1.4 episodes per 1000 patients among all infants, from 24.2 to 11.6 episodes per 1000 patients among infants with a birth weight of 750-999 g, and from 82.7 to 23.8 episodes per 1000 patients among infants with a birth weight <750 g. Fluconazole prophylaxis use increased among all infants with a birth weight <1000 g (or <1500 g), with the largest effect on birth weights <750 g, increasing from 3.8 per 1000 patients in 1997 to 110.6 per 1000 patients in 2010. The use of broad-spectrum antibacterial antibiotics decreased among all infants from 275.7 per 1000 patients in 1997 to 48.5 per 1000 patients in 2010. The use of empirical antifungal therapy increased over time from 4.0 per 1000 patients in 1997 to 11.5 per 1000 patients in 2010. CONCLUSIONS: The incidence of invasive candidiasis in the NICU decreased over the 14-year study period. Increased use of fluconazole prophylaxis and empirical antifungal therapy, along with decreased use of broad-spectrum antibacterial antibiotics, may have contributed to this observation.
Authors: Amit S Chitnis; Shelley S Magill; Jonathan R Edwards; Tom M Chiller; Scott K Fridkin; Fernanda C Lessa Journal: Pediatrics Date: 2012-06-18 Impact factor: 7.124
Authors: William W Hope; P Brian Smith; Antonio Arrieta; Donald N Buell; Michael Roy; Atsunori Kaibara; Thomas J Walsh; Michael Cohen-Wolkowiez; Daniel K Benjamin Journal: Antimicrob Agents Chemother Date: 2010-03-22 Impact factor: 5.191
Authors: Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole Journal: Pediatrics Date: 2002-08 Impact factor: 7.124
Authors: Daniel K Benjamin; Elizabeth R DeLong; William J Steinbach; Charles M Cotton; Thomas J Walsh; Reese H Clark Journal: Pediatrics Date: 2003-09 Impact factor: 7.124
Authors: Julie Autmizguine; Sylvia Tan; Michael Cohen-Wolkowiez; C Michael Cotten; Nathan Wiederhold; Ronald N Goldberg; Ira Adams-Chapman; Barbara J Stoll; P Brian Smith; Daniel K Benjamin Journal: Pediatr Infect Dis J Date: 2018-09 Impact factor: 2.129
Authors: Amanda B Arsenault; Kearney T W Gunsalus; Sonia S Laforce-Nesbitt; Lynn Przystac; Erik J DeAngelis; Michaela E Hurley; Ethan S Vorel; Richard Tucker; Nirupa R Matthan; Alice H Lichtenstein; Carol A Kumamoto; Joseph M Bliss Journal: Pediatr Infect Dis J Date: 2019-02 Impact factor: 2.129
Authors: Kevin R Ellsworth; Marc A Ellsworth; Amy L Weaver; Kristin C Mara; Reese H Clark; William A Carey Journal: JAMA Pediatr Date: 2018-07-02 Impact factor: 16.193
Authors: D Wei; C Osman; D Dukhovny; J Romley; M Hall; S Chin; T Ho; P S Friedlich; A Lakshmanan Journal: J Perinatol Date: 2016-07-28 Impact factor: 2.521
Authors: Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel Journal: Clin Infect Dis Date: 2015-12-16 Impact factor: 9.079